ClinicalTrials.gg
RecruitingNCT03980002BDHCLL001Updated Jun 10, 2019

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

A Phase 2 interventional study of FCR and Ibrutinib and BR and Ibrutinib in Chronic Lymphocytic Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-10.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2022, 3 years 11 months ago, but the record still lists the study as recruiting.
  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
39th of 83
50 · median 44
Started
2019
with 6 others
Phase 2
43 of 83
6 open now
Primary completion
2022-12
later than 8 of 27 live
Registered
67th of 83
by date

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 39th largest by planned enrollment, is one of 7 that started in 2019, is one of 43 in phase 2, reaches primary completion later than 8 of the 27 other live ones, and was the 67th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Chronic Lymphocytic Leukemia
  • Therapeutics
  • ibrutinib
  • fludarabine
  • rituximab
  • bendamustine
  • cyclophosphamide
  • treatment-naive
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women ≥ 18 years and ≤ 75 of age.
  2. Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria.
  3. Treatment-naive patients. Those patients received short-term substandard treatment are permitted if meet all the items listed below:

    1. Untreated with combined chemotherapy such as CHOP ,COP and so on.
    2. Unteated with chemotherapy regimens including fludarabine and bendamustine.
    3. Unteated with Ibrutinib.
    4. If treated with chlorambucil or cyclophosphamide,should less than 3 weeks.
    5. If treated with interferon, should less than 6 months.
    6. No objective response are achieved (PR or CR).
  4. CLL/SLL requiring treatment as defined by at least one of the following criteria:

    1. Development of, or worsening of, anemia to \<100g/L (non-hemolytic) .
    2. Development of, or worsening of, thrombocytopenia to \<100,000/L.
    3. Massive (≥ 6 cm below left costal margin), progressive or symptomatic splenomegaly.
    4. Massive nodes (≥ 10 cm in longest diameter), or progressive or symptomatic lymphadenopathy .
    5. Progressive lymphocytosis with an increase of > 50% over a 2-month period or lymphocyte-doubling time of \< 6 months. Lymphocyte-doubling time may be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In patients with initial blood lymphocyte counts of \< 30,000/L, LDT should not be used as a single parameter to define treatment indication. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL/SLL (eg, infection, use ) should be excluded. f)Symptomatic or functional extranodal sites involved s (eg. Skin,kidney, lungs and so on).

    g)Constitutional symptoms, defined as any 1 or more of the following disease-related symptoms or signs: i. Unintentional weight loss of ≥ 10% within the previous 6 months ii.Significant fatigue (ie, inability to work or perform usual activities)

  5. (ECOG) performance status of 0 to 2.
  6. Expected to survival period for 3 months or more.

Exclusion criteria

Exclusion Criteria:

  1. History of malignant tumour except CLL in the past 1year(including active central nervous system (CNS) involvement with lymphoma).
  2. Transformed to large cell lymphoma manifested by clinical evidence, or progressed to prolymphocytic leukemia(PLL).
  3. Have active hemolytic anemia or idiopathic thrombocytopenic purpura, and require treatment.
  4. Inadequate hepatic and renal function defined as: and ALT >4.0 x (ULN), >2.0 x upper limit of normal (ULN), Adequate renal function defined by serum creatinine >1.5 x upper limit of normal (ULN),unrelated to lymphoma.
  5. Severe or uncontrolled infection.
  6. Central nervous system (CNS) dysfunction with clinical manifestation.
  7. Other serious medical diseases that may affect the study(eg. Uncontrolled diabetes, gastric ulcer, other severe cardiopulmonary disease),and final decided by the investigator.
  8. Ongoing and uncontrolled bleeding
  9. History of major life-threatening bleeding, especially due to irreversible cause.
  10. Requirement for continuous anticoagulation drugs.
  11. Major surgery within 30 days(excluding lymph node ).
  12. Pregnant or Lactating women, or women of reproductive age refusal to take measures.
  13. Allergy to any drug used in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    FCR/BR alternating with ibrutinib

    FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy

    Drug: FCR and Ibrutinib · Drug: BR and Ibrutinib · Drug: Ibrutinib and Thalidomide

Interventions

  • DrugFCR and Ibrutinib

    Drug page: IbrutinibStudies of IbrutinibIbrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Induction treatment: Patients \<65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count \<10×10\^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles. 1. FCR: F(Fludarabine):25mg/m2·d,d1-3; C(Cyclophosphamide):CTX 250mg /m2·d,d1-3; R(Rituximab):375mg/m2 d0(first course),500mg/m2 d0(subsequent courses); 2. Ibrutinib:420mg/d

  • DrugBR and Ibrutinib

    Drug page: IbrutinibStudies of IbrutinibIbrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Induction treatment: Patients ≥65y and ≤75 y or \<65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10\^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR: B(Bendamustine):90mg/m2·d,d1-2; R(Rituximab):375mg/m2 d0(first course),500mg/m2 d0(subsequent courses); 2. Ibrutinib: 420mg/d

  • DrugIbrutinib and Thalidomide

    Drug pages: IbrutinibStudies of IbrutinibIbrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ThalidomideStudies of ThalidomideThalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Maintenance treatment: After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy.

06

What researchers measure

Primary outcomes

  1. CRR

    Rate of complete remission

    Time frame: 3 months after completion of induction therapy

Secondary outcomes

  1. ORR

    Overall Response Rate

    Time frame: 3 months after completion of induction therapy

  2. OS

    Overall survival

    Time frame: 5 years

  3. PFS

    Progression-free survival

    Time frame: 5 years

  4. MRD negative rate

    the rate of undetectable tumor cells in bone marrow and/or peripheral blood by multicolor flow cytometry

    Time frame: 3 months after completion of induction therapy

  5. DoR

    Duration of Response

    Time frame: 5 years

  6. Treatment-related side effects

    Time frame: 10 months

07

Study locations

1 of 1 sites recruiting
  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
    Tianjin, Tianjin 30020, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Dec 2022, 43 months after the start.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 43 months is below that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2019
First posted
Jun 10, 2019
StartActual
May 15, 2019
Primary completionEst.
Dec 15, 2022
CompletionEst.
Dec 30, 2027
Last update
Jun 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03980002
Responsible party
TingyuWang (Attending doctor, Institute of Hematology & Blood Diseases Hospital, China) — Principal investigator
First posted
Jun 10, 2019
Start date
May 15, 2019
Primary completion
Dec 15, 2022 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jun 10, 2019

Study contacts

Zengjun Li
Contact
lizengjun@ihcams.ac.cn
+86 13642138692
Tingyu Wang
Contact
wangtingyu@ihcams.ac.cn
+86 15692201678
Zengjun Li
principal investigator · Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Thalidomide

Start the discussion